natgillin/translations-raw huggingface dataset:
Adverse events of the haematologic system, including medically significant cytopoenia (e.g. thrombocytopaenia, leucopaenia) have been reported with Humira.
U bolesnika liječenih lijekom Humira prijavljeni su štetni događaji u hematološkom sustavu, uključujući medicinski značajne citopenije (npr. trombocitopenija, leukopenija).
Adverse events or laboratory abnormalities led to 5% of patients withdrawing from Pegasys treatment, while less than 1% of patients withdrew from lamivudine treatment for these reasons.
Nuspojave ili poremećaji u laboratorijskim parametrima doveli su do povlačenja 5% bolesnika iz liječenja lijekom Pegasys, dok je iz liječenja lamivudinom iz istih razloga povučeno manje od 1% bolesnika.
Adverse events that occurred at an increased incidence of ≥5% in the supratherapeutic dose period compared with the therapeutic dose period were headache, generalised rash, and increased transaminase.
Štetni događaji koji su nastajali povećanom incidencijom od ≥ 5% u razdoblju supraterapijske doze u usporedbi s razdobljem terapijske doze bili su glavobolja, generalizirani osip i povišene transaminaze.
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
Prijavljivanje nuspojava prema značaju; tj. fatalne i životno ugrožavajuće nuspojave, teške neočekivane nuspojave, nuspojave od posebnog interesa (AESI).
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
Štetni događaji koje je prvenstveno važno prijaviti, npr. fatalne i po život opasne nuspojave, neočekivane teške nuspojave, štetni događaji od posebnog interesa (AESI).
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
Štetni događaji koje prvenstveno treba prijaviti, tj. smrtonosne i po život opasne nuspojave, neočekivane ozbiljne nuspojave, štetni događaji od posebnog interesa (AESI).
adverse events upon the initiation of co-
bubrega i nuspojava povezanih s primjenom takrolimusa nakon početka istodobne primjene.
Adverse events were experienced by 88% of Pegasys-treated patients as compared with 53% of patients in the lamivudine comparator group, while 6% of the Pegasys-treated and 4% of the lamivudine-treated patients experienced serious adverse events during the studies.
Nuspojave su se pojavile u 88% bolesnika liječenih lijekom Pegasys u usporedbi s 53% bolesnika u usporednoj skupini liječenoj lamivudinom, dok su se u 6% bolesnika liječenih lijekom Pegasys i 4% bolesnika liječenih lamivudinom tijekom ispitivanja pojavile ozbiljne nuspojave.
Adverse events were more frequent in females and in patients more than 65 years of age in both the bivalirudin and the heparin-treated comparator groups compared to male or younger patients.
U usporedbi s muškim ili mlađim bolesnicima, nuspojave su bile učestalije u žena i bolesnika starijih od 65 godina u obje uspoređivane grupe ispitanika - liječeni bivalirudinom ili heparinom.
Adverse events(s)
Nuspojava
Adverse experiences including prolongation of coagulation markers and liver abnormalities Moderate to severe adverse experiences may require modification of the patient's dose regimen, or in some cases, termination of IntronA therapy.
Neželjeni učinci uključujući produljeno vrijeme zgrušavanja krvi i poremećaje funkcije jetre Umjereni do teški neželjeni učinci mogu zahtijevati promjenu režima doziranja ili, u nekim slučajevima, prekid liječenja lijekom IntronA.
Adverse experiences such as oesophagitis, oesophageal ulcers and oesophageal erosions, in some cases severe and requiring hospitalization, rarely with bleeding or followed by oesophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates.
U bolesnika koji peroralno primaju bisfosfonate prijavljeni su štetni događaji kao što su ezofagitis, vrijedovi jednjaka i erozije jednjaka koji su u nekim slučajevima bili teški i zahtijevali su bolničko liječenje, rijetko s krvarenjem ili strikturom jednjaka ili perforacijom.
Adverse re action
Nuspojava
Adverse Reaction
benigne neoplazme
Adverse reaction
glomerulonefropatija
Adverse Reaction
kašalj
Adverse reaction
Nuspojav a
Adverse reaction
Nuspojava
Adverse reaction
Nuspojave
Adverse Reaction
parestezije (uključujući hipoesteziju),
Adverse reaction
Poremećaji oka
Adverse reaction
reakcije na infuziju
Adverse reaction
Učestalost nuspojava
Adverse reaction (MedDRA Preferred Term)
Nuspojave (MedDRA preporučeni izraz)
Adverse Reaction (Medicinal Product*)
Nuspojava (lijek*)
Adverse Reaction (Preferred Term)
Nuspojava (preferirani naziv)
Adverse reaction after previous HALAVEN administration
Nuspojava nakon prethodne primjene lijeka HALAVEN
Adverse reaction and severity
Nuspojava i težina
Adverse reaction data was taken from a total of 413 clinical trial patients with severe Primary IGFD.
Podaci o nuspojavama uzeti su od ukupno 413 bolesnika s teškom primarnom deficijencijom IGF uključenih u kliničko ispitivanje.
Adverse reaction frequencies are reported as: Very common (≥ 1/10)
Učestalost nuspojava prikazana je na sljedeći način: Vrlo često (≥ 1/10)
Adverse Reaction Frequency of adverse reactions1
Nuspojava Učestalost nuspojava1
Adverse reaction frequency was estimated primarily based on summation of unique Cinryze-related adverse events reported across 8 completed clinical studies in HAE subjects.
Učestalost nuspojava bila je procijenjena prvenstveno na temelju zbroja jedinstvenih nuspojava povezanih s lijekom Cinryze zabilježenih u 8 dovršenih kliničkih ispitivanja u ispitanika s hereditarnim angioedemom (HAE).
Adverse reaction frequency**
Učestalost nuspojave
Adverse Reaction Management Guide
Vodič za zbrinjavanje nuspojava
Adverse Reaction Rates in Retroperitoneal or Intra-Abdominal Surgery Study
Stopa nuspojava u kliničkim ispitivanjima u retroperitonealnoj ili intraabdominalnoj kirurgiji
Adverse reaction terms
Izrazi nuspojava
Adverse Reactiona
Nuspojavaa
Adverse reactions
Nuspojava
Adverse reactions
Nuspojave
Adverse reactions
Rijetko
Adverse Reactions (ARs) have been collected from one phase I study with healthy subjects (n = 28) and two phase III studies in patients with primary immunodeficiency (n = 100) with Hizentra.
Nuspojave na liječenje Hizentrom prikupljene su iz jedne kliničke studije faze I sa zdravim ispitanicima (n = 28) i dvije kliničke studije faze III s ispitanicima s primarnom imunodeficijencijom (n = 100).
Adverse reactions (for all age groups) considered as being at least possibly related to vaccination have been categorised by frequency.
Nuspojave (u svim dobnim skupinama), koje se smatraju barem moguće povezanima s cijepljenjem su kategorizirane prema učestalosti.
Adverse reactions (frequency and seriousness)
6 Nuspojave (učestalost i ozbiljnost)
Adverse reactions (frequency and seriousness)
Nuspojave (učestalost i ozbiljnost)
Adverse reactions (frequency and seriousness) For dogs and cats:
Nuspojave (učestalost i ozbiljnost) Za pse i mačke:
Adverse reactions (frequency and seriousness) Rabbits:
Nuspojave (učestalost i ozbiljnost) Kunići:
Adverse reactions (frequency and seriousness)*
Nuspojave (učestalost i ozbiljnost)
Adverse reactions (frequency)
Nuspojave (učestalost)
Adverse reactions (frequency* and seriousness)
Nuspojave (učestalost i ozbiljnost)
Adverse reactions (i.e. considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported at similar frequencies for Cubicin and comparator regimens.
Učestalost zabilježenih nuspojava (za koje je istraživač ocijenio da su možda, vjerojatno ili sigurno povezane s lijekom) bila je slična za Cubicin i lijekove usporedbe.
Adverse Reactions (Infants, Children and Adolescents)
Nuspojave (Dojenčad, djeca i adolescenti)
Adverse reactions according to frequency
Nuspojave prema učestalosti
Adverse reactions additionally reported after booster vaccination of primary series and/or catch-up vaccination:
Nuspojave dodatno prijavljene nakon docjepljivanja u primarnoj seriji cijepljenja i/ili nakon naknadne provedbe propuštene ili odgođene uobičajene vakcinacije:
Adverse reactions affecting the MedDRA system organ class ‘Blood and lymphatic system disorders’ subsided during continued nitisinone treatment.
Nuspojave koje zahvaćaju organski sustav "Poremećaji krvi i limfnog sustava" prema MedDRA-klasifikaciji organskih sustava povukle su se tijekom kontinuiranog liječenja nitizinonom.
Adverse reactions and laboratory abnormalities reported in patients treated with the ZALTRAP/FOLFIRI regimen compared to patients treated with the placebo/FOLFIRI regimen are listed in Table 1 according to MedDRA system organ class and frequency categories.
Nuspojave i laboratorijska odstupanja prijavljena u bolesnika liječenih protokolom ZALTRAP/FOLFIRI u usporedbi s bolesnicima koji su primali protokol placebo/FOLFIRI navedeni su u Tablici 1 prema MedDRA klasifikaciji organskih sustava i kategorijama učestalosti.
Adverse reactions and their frequencies are reported in Table 1.
Nuspojave i njihove incidencije navedene su u Tablici 1.
Adverse reactions and their frequencies are reported in table 1.
Nuspojave i njihove učestalosti prikazane su u tablici 1.
Adverse reactions and their frequencies are reported in Table 1.
Nuspojave i njihove učestalostinavedene su u Tablici 1.
Adverse reactions are classified according to MedDRA System Organ Class and frequency.
Nuspojave su kategorizirane prema MedDRA klasifikaciji organskih sustava i učestalosti.
Adverse reactions are classified according to system organ class and frequency.
Nuspojave su razvrstane prema organskim sustavima i učestalosti.
Adverse reactions are classified by preferred term and System Organ Class, and by frequency.
Nuspojave su klasificirane prema preporučenom izrazu i organskom sustavu te prema učestalosti.
Adverse reactions are defined as those adverse events that occurred at a higher frequency in the dinutuximab, GM- CSF, IL-2 and isotretinoin-treated group compared with the isotretinoin-treated control group during the ANBL0032 randomised, controlled, pivotal study, and that have a plausible mechanistic relationship to treatment with dinutuximab.
Nuspojave su definirane kao štetni događaji koji su se pojavili češće u skupini liječenoj dinutuksimabom, GM-CSF-om, IL-2 i izotretinoinom u usporedbi s kontrolnom skupinom liječenom izotretinoinom tijekom randomiziranog, kontroliranog, pivotalnog ispitivanja ANBL0032, a koje imaju vjerojatnu vezu, s obzirom na mehanizam djelovanja, s liječenjem dinutuksimabom.
Adverse reactions are derived from an integrated safety analysis including 12 clinical studies.
Nuspojave potječu iz integrirane sigurnosne analize koja je uključivala 12 kliničkih ispitivanja.
Adverse reactions are listed according to MedDRA system organ class.
Nuspojave su navedene prema organskom sustavu po MedDRA-i.
Adverse reactions are listed according to the following categories: Very common (1/10)
Nuspojave su navedene prema sljedećim kategorijama: Vrlo često (1/10)
Adverse reactions are listed according to the following categories: Very common: 1/10
Nuspojave su svrstane prema sljedećim kategorijama: Vrlo često: ≥ 1/10
Adverse reactions are listed according to the following frequencies: Very common: ≥ 1/10
Nuspojave su navedene prema sljedećoj učestalosti: Vrlo često: ≥ 1/10
Adverse reactions are listed according to the following frequency: Very Common (≥1/10)
Nuspojave su navedene u nastavku prema sljedećoj učestalosti: vrlo često (≥1/10)
Adverse reactions are listed below by MedDRA body system organ class and by frequency.
Dolje navedene nuspojave u skladu su s MedDRA klasifikacijom organskih sustava i učestalosti.
Adverse reactions are listed below by MedDRA preferred term system organ class and by frequency.
Nuspojave su navedene prema MedDRA preporučenim izrazima klasifikacije organskih sustava i prema učestalosti.
Adverse reactions are listed below by MedDRA system organ class and by frequency.
Nuspojave su u nastavku navedene prema MedDRA-inoj klasifikaciji organskih sustava i učestalosti.
Adverse reactions are listed below in Table 1 by system organ class and frequency (frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene niže u tablici 1 prema klasifikaciji organskih sustava i učestalosti (učestalosti su definirane kao: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥ 1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su niže navedene prema sljedećoj učestalosti: vrlo često (1/10); često (1/100 i <1/10); manje često (1/1000 i <1/100) ; rijetko (1/10 000 i <1/1000) ; vrlo rijetko (<1/10 000) ; nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are listed by MedDRA system organ class and absolute frequency.
Nuspojave su navedene prema MedDRA klasifikaciji po organskim sustavima i apsolutnoj učestalosti.
Adverse reactions are listed by System Organ Class (see Table 3).
Nuspojave su navedene prema organskim sustavima (vidjeti Tablicu 3).
Adverse reactions are listed by System Organ Class and frequency.
Nuspojave su navedene prema organskim sustavima i učestalosti.
Adverse reactions are listed by system organ class and frequency.
Nuspojave su prikazane prema organskom sustavu i učestalosti.
Adverse reactions are listed in Table 1 below
Nuspojave su navedene u Tablici 1 dalje u tekstu.
Adverse reactions are listed in Table 1below.
Nuspojave su navedene u Tablici 1 dalje u tekstu.
Adverse reactions are listed in table 2 according to MedDRA system organ class and frequency categories.
Nuspojave u Tablici 2 navedene su prema MedDRA klasifikaciji organskih sustava i kategorijama učestalosti.
Adverse reactions are listed in Table 2 according to MedDRA system organ class and frequency categories.
U tablici 2 navedene su nuspojave prema MedDRA klasifikaciji organskih sustava i kategorijama učestalosti.
Adverse reactions are listed in Table 2.
Nuspojave su popisane u Tablici 2.
Adverse reactions are listed in Table 5 by regimen, system organ class and frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000).
Nuspojave su u Tablici 5 popisane prema režimu, organskim sustavima i učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100) rijetko (≥1/10 000 i <1/1000) i vrlo rijetko (<1/10 000).
Adverse reactions are listed inTable 1 below.
Nuspojave su navedene u Tablici 1 dalje u tekstu.
Adverse reactions are presented by system organ class.
Nuspojave su prikazane prema organskim sustavima.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova je učestalost definirana na sljedeći način: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000) i vrlo rijetko (<1/10 000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000).
Nuspojave su prikazane u padajućem nizu prema ozbiljnosti i njihova učestalost je definirana na sljedeći način: vrlo često: (≥1/10); često: (≥1/100 do <1/10); manje često: (≥1/1000 do <1/100); rijetko: (≥1/10 000 do <1/1000) i vrlo rijetko: (<1/10 000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to<1/100); rare (≥1/10,000 to<1/1,000) and very rare (<1/10,000)
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova učestalost je definirana na sljedeći način: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000) i vrlo rijetko (<1/10 000).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema klasifikaciji organskih sustava, koristeći iduću konvenciju: vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
Nuspojave su navedene prema klasifikaciji organskih sustava primjenom sljedeće konvencije: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema klasifikaciji organskih sustava, koristeći iduću konvenciju: vrlo često (≥1/10), često (≥1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to <1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema klasifikaciji organskih sustava, koristeći iduću konvenciju: vrlo često (≥1/10), često (≥1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked by system organ class and frequency ([very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000)]).
Nuspojave su navedene prema klasifikaciji organskih sustava i učestalosti ([vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000)]).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000).
Nuspojave su poredane prema učestalosti javljanja koristeći sljedeće pravilo: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10000, <1/1000), very rare (<1/10000).
Nuspojave su poredane prema učestalosti javljanja koristeći sljedeće pravilo: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention:
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave:
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Nuspojave su razvrstane prema sljedećim kriterijima učestalosti, pri čemu se prvo navode one najčešće: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (< 1/10 000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common 1/10), common 1/100 to <1/10), uncommon 1/1,000 to <1/100), rare 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions associated with Brimica Genuair were similar to those of the individual components.
Nuspojave povezane s Brimica Genuairom bile su slične onima pojedinačnih sastavnica.
Adverse reactions associated with Duaklir Genuair were similar to those of the individual components.
Nuspojave povezane s Duaklir Genuairom bile su slične onima pojedinačnih sastavnica.
Adverse reactions associated with PR interval prolongation (e.g.
Mogu se pojaviti nuspojave povezane s produljenim PR intervalom (npr.
Adverse reactions associated with the mode of action of selexipag have been observed frequently, in particular during the phase of individualised dose titration, and are tabulated below:
Nuspojave povezane s načinom djelovanja seleksipaga uočene su često, posebice tijekom faze individualizirane titracije doze; navedene su u tablici ispod: